DE69133557D1 - Homologe rekombination in säugetier-zellen - Google Patents

Homologe rekombination in säugetier-zellen

Info

Publication number
DE69133557D1
DE69133557D1 DE69133557T DE69133557T DE69133557D1 DE 69133557 D1 DE69133557 D1 DE 69133557D1 DE 69133557 T DE69133557 T DE 69133557T DE 69133557 T DE69133557 T DE 69133557T DE 69133557 D1 DE69133557 D1 DE 69133557D1
Authority
DE
Germany
Prior art keywords
mammalian cells
homologous recombination
methods
transgenic
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69133557T
Other languages
English (en)
Inventor
Robert M Kay
Anton Berns
Paul Krimpenfort
Frank Pieper
Rein Strijker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharming Intellectual Property BV
Original Assignee
Pharming Intellectual Property BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharming Intellectual Property BV filed Critical Pharming Intellectual Property BV
Application granted granted Critical
Publication of DE69133557D1 publication Critical patent/DE69133557D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/206—Pseudochromosomes, minichrosomosomes of yeast origin, e.g. YAC, 2u
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
DE69133557T 1990-08-29 1991-08-28 Homologe rekombination in säugetier-zellen Expired - Lifetime DE69133557D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57474790A 1990-08-29 1990-08-29
PCT/US1991/005917 WO1992003917A1 (en) 1990-08-29 1991-08-28 Homologous recombination in mammalian cells

Publications (1)

Publication Number Publication Date
DE69133557D1 true DE69133557D1 (de) 2007-03-15

Family

ID=24297465

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69133557T Expired - Lifetime DE69133557D1 (de) 1990-08-29 1991-08-28 Homologe rekombination in säugetier-zellen

Country Status (8)

Country Link
US (2) US5612205A (de)
EP (1) EP0546091B1 (de)
JP (1) JPH06506105A (de)
AT (1) ATE352612T1 (de)
AU (1) AU664976B2 (de)
CA (1) CA2090473A1 (de)
DE (1) DE69133557D1 (de)
WO (1) WO1992003917A1 (de)

Families Citing this family (464)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048729A (en) * 1987-05-01 2000-04-11 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
US5633076A (en) * 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993004171A1 (en) * 1991-08-19 1993-03-04 Symbicom Aktiebolag Human beta-casein, process for producing it and use thereof
WO1993004169A1 (en) * 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US7217571B1 (en) * 1991-08-21 2007-05-15 The Regents Of The University Of California Gene therapy by small fragment homologous replacement
US5641670A (en) * 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US6054288A (en) * 1991-11-05 2000-04-25 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
US6692737B1 (en) 1991-11-05 2004-02-17 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
US6063630A (en) * 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
US5733761A (en) * 1991-11-05 1998-03-31 Transkaryotic Therapies, Inc. Protein production and protein delivery
NZ245015A (en) * 1991-11-05 1995-12-21 Transkaryotic Therapies Inc Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
US20020108136A1 (en) * 1997-03-21 2002-08-08 Sri Transgenic animals produced by homologous sequence targeting
WO1993023553A1 (en) * 1992-05-19 1993-11-25 Exemplar Corporation Production of transgenics by joining regulatory and coding regions in vivo
US6531124B1 (en) 1992-07-10 2003-03-11 Transkaryotic Therapies, Inc. In vivo production and delivery of insulinotropin for gene therapy
US6670178B1 (en) 1992-07-10 2003-12-30 Transkaryotic Therapies, Inc. In Vivo production and delivery of insulinotropin for gene therapy
EP0656747A4 (de) * 1992-08-21 1997-05-07 Univ California Zusammensetzung und verfahren zur änderung von dns-sequenzen durch homologe rekombination.
AU7677894A (en) * 1993-08-30 1995-03-22 Northwestern University Rat pluripotent embryonic stem cells and method of obtaining and using same
US5750176A (en) * 1994-03-09 1998-05-12 Abbott Laboratories Transgenic non-human mammal milk comprising 2'-fucosyl-lactose
NZ281041A (en) * 1994-03-09 1998-04-27 Abbott Lab Non-human mammals transformed with a catalytic entity of enzymes or antibodies to produce a heterologous product in the animals milk
US6204431B1 (en) 1994-03-09 2001-03-20 Abbott Laboratories Transgenic non-human mammals expressing heterologous glycosyltransferase DNA sequences produce oligosaccharides and glycoproteins in their milk
WO1995024494A1 (en) * 1994-03-09 1995-09-14 Abbott Laboratories Humanized milk
US6576236B1 (en) 1994-07-01 2003-06-10 Dana Farber Cancer Institute Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
US5728557A (en) * 1995-06-01 1998-03-17 Merck & Co., Inc. Method of making herpes simplex type 1 mutants and mutants so produced
US6632976B1 (en) 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
US6077697A (en) * 1996-04-10 2000-06-20 Chromos Molecular Systems, Inc. Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US20030033617A1 (en) * 1996-04-10 2003-02-13 Gyula Hadlaczky Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US20020160970A1 (en) * 1996-04-10 2002-10-31 Gyula Hadlaczky Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US6326204B1 (en) 1997-01-17 2001-12-04 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
EP1007732B1 (de) 1997-01-17 2006-07-26 Maxygen, Inc. EVOLUTION Prokaryotischer GANZER ZELLEN DURCH REKURSIVE SEQUENZREKOMBINATION
US7148054B2 (en) * 1997-01-17 2006-12-12 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
US6011197A (en) 1997-03-06 2000-01-04 Infigen, Inc. Method of cloning bovines using reprogrammed non-embryonic bovine cells
US5948653A (en) * 1997-03-21 1999-09-07 Pati; Sushma Sequence alterations using homologous recombination
DK1000167T4 (da) * 1997-07-23 2011-08-08 Roche Diagnostics Gmbh Fremstilling af humane muterede proteiner i menneskeceller ved homolog rekombination
US6207442B1 (en) * 1997-10-16 2001-03-27 Zymogenetics, Inc. Plasmid construction by homologous recombination
EP1036198B1 (de) 1997-12-08 2012-09-26 California Institute Of Technology Verfahren zur Herstellung von Polynukleotid- und Polypeptidsequenzen
US20020029391A1 (en) * 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
US6438561B1 (en) * 1998-11-19 2002-08-20 Navigation Technologies Corp. Method and system for using real-time traffic broadcasts with navigation systems
US6700037B2 (en) 1998-11-24 2004-03-02 Infigen, Inc. Method of cloning porcine animals
US6258998B1 (en) 1998-11-24 2001-07-10 Infigen, Inc. Method of cloning porcine animals
PT1137762E (pt) 1998-12-07 2009-01-14 Genzyme Corp Tratamento da doença de pompe
EE05627B1 (et) * 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
DK2112166T3 (en) 1998-12-23 2019-02-04 Pfizer Human monoclonal antibodies to CTLA-4
WO2000042559A1 (en) * 1999-01-18 2000-07-20 Maxygen, Inc. Methods of populating data structures for use in evolutionary simulations
US20030054390A1 (en) * 1999-01-19 2003-03-20 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US6368861B1 (en) 1999-01-19 2002-04-09 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US6917882B2 (en) * 1999-01-19 2005-07-12 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US6376246B1 (en) 1999-02-05 2002-04-23 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US6961664B2 (en) 1999-01-19 2005-11-01 Maxygen Methods of populating data structures for use in evolutionary simulations
US7024312B1 (en) * 1999-01-19 2006-04-04 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US20070065838A1 (en) * 1999-01-19 2007-03-22 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
EP2253704B1 (de) 1999-01-19 2015-08-19 Codexis Mayflower Holdings, LLC Durch Oligonukleotide-vermittelte Nukleinsäuren-rekombination
US6890726B1 (en) 1999-04-06 2005-05-10 Oklahoma Medical Research Foundation Method for selecting recombinase variants with altered specificity
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
EP2829609A1 (de) 1999-08-24 2015-01-28 E. R. Squibb & Sons, L.L.C. Humane Antikörper gegen CTLA-4-Antikörper und Verwendungen davon
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US6534300B1 (en) * 1999-09-14 2003-03-18 Genzyme Glycobiology Research Institute, Inc. Methods for producing highly phosphorylated lysosomal hydrolases
US6770468B1 (en) 1999-09-14 2004-08-03 Genzyme Glycobiology Research Institute, Inc. Phosphodiester-α-GlcNAcase of the lysosomal targeting pathway
US6908612B2 (en) 1999-10-08 2005-06-21 University Of Maryland Biotechnology Institute Virus coat protein/receptor chimeras and methods of use
US7430477B2 (en) 1999-10-12 2008-09-30 Maxygen, Inc. Methods of populating data structures for use in evolutionary simulations
US7820878B2 (en) * 1999-11-19 2010-10-26 Kyowa Hakko Kirin Co., Ltd. Production of ungulates, preferably bovines that produce human immunoglobulins
US7414170B2 (en) * 1999-11-19 2008-08-19 Kirin Beer Kabushiki Kaisha Transgenic bovines capable of human antibody production
US7074983B2 (en) * 1999-11-19 2006-07-11 Kirin Beer Kabushiki Kaisha Transgenic bovine comprising human immunoglobulin loci and producing human immunoglobulin
AU1777301A (en) * 1999-11-19 2001-05-30 Hematech, Llc Production of ungulates, preferably bovines that produce human immunoglobulins
EP2360184A3 (de) * 2000-02-10 2011-11-16 Abbott Laboratories Antikörper zum Binden von humanem Interleukin-18 und Herstellungs- und Verwendungsverfahren
CA2403205A1 (en) 2000-03-13 2001-09-20 Engene, Inc. Compositions and methods of regulated protein expression in gut endocrine k cells
WO2001070763A1 (en) * 2000-03-22 2001-09-27 The Children's Hospital Of Philadelphia Modified blood clotting factors and methods of use
US7045314B2 (en) * 2000-04-04 2006-05-16 Baxter International Inc. Method for the production of bacterial toxins
US6686180B2 (en) * 2000-04-04 2004-02-03 Baxter International Inc. Method for the production of bacterial toxins
ES2343351T3 (es) 2000-06-08 2010-07-29 Immune Disease Institute, Inc. Procedimientos y composiciones para inhibir la lesion por reperfusion mediada por inmunoglobulina.
CA2634294A1 (en) * 2000-08-03 2002-02-14 Therapeutic Human Polyclonals, Inc. Production of humanized antibodies in transgenic animals
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
EP2166087B1 (de) * 2000-09-28 2012-11-14 Bioriginal Food & Science Corp. FAD6, Mitglied der Desaturase-Familie und Verwendungen davon
US20020142397A1 (en) 2000-12-22 2002-10-03 Philippe Collas Methods for altering cell fate
DE60144248D1 (de) 2000-12-22 2011-04-28 Kyowa Hakko Kirin Co Ltd Verfahren zur klonierung von nichtmenschliche säugern unter verwendung von reprogrammiertem donorchromatin oder donorzellen
US7491534B2 (en) * 2000-12-22 2009-02-17 Kirin Holdings Kabushiki Kaisha Methods for altering cell fate to generate T-cells specific for an antigen of interest
PE20020801A1 (es) * 2001-01-05 2002-09-06 Pfizer Anticuerpos contra el receptor del factor de crecimiento similar a insulina
AU2002254431A1 (en) * 2001-03-27 2002-10-08 M. Eric Gershwin Antibodies against autoantigens of primary biliary cirrhosis and methods of making and using them
AUPR446701A0 (en) * 2001-04-18 2001-05-17 Gene Stream Pty Ltd Transgenic mammals for pharmacological and toxicological studies
WO2002085924A2 (en) * 2001-04-23 2002-10-31 Abgenix, Inc. ANTI-α3(IV)NC1 MONOCLONAL ANTIBODIES AND ANIMAL MODEL FOR HUMAN ANTI-GLOMERULAR BASEMENT MEMBRANE AUTOANTIBODY DISEASE
JP4619651B2 (ja) 2001-06-01 2011-01-26 コーネル・リサーチ・ファンデーション・インコーポレイテッド 前立腺特異的膜抗原に対する修飾抗体およびその使用
WO2002102830A1 (en) * 2001-06-15 2002-12-27 New Century Pharmaceuticals, Inc. Human albumin animal models for drug evaluation, toxicology and immunogenicity studies
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
WO2003028630A2 (en) 2001-10-04 2003-04-10 Genetics Institute Llc. Methods and compositions for modulating interleukin-21 receptor activity
US20040139489A1 (en) * 2001-10-05 2004-07-15 Robert Lanza Method for generating cloned animals using chromosome shuffling
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US6800472B2 (en) * 2001-12-21 2004-10-05 Genzyme Glycobiology Research Institute, Inc. Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester α-N-acetyl glucosimanidase
US20030124652A1 (en) * 2001-12-21 2003-07-03 Novazyme Pharmaceuticals, Inc. Methods of producing high mannose glycoproteins in complex carbohydrate deficient cells
US6905856B2 (en) * 2001-12-21 2005-06-14 Genzyme Glycobiology Research Institute, Inc. Soluble GlcNAc phosphotransferase
US6578724B1 (en) * 2001-12-29 2003-06-17 United States Can Company Connector for use in packaging aerosol containers
WO2003065997A2 (en) 2002-02-06 2003-08-14 Vicor Technologies, Inc. Anti-infarction molecules
EP1534729A2 (de) * 2002-02-26 2005-06-01 University of Utah Research Foundation Mit bluthochdruck und virusknospung assoziierte nedd4l-varianten
ES2327830T3 (es) * 2002-03-29 2009-11-04 Schering Corporation Anticuerpos monoclonales humanos anti-interleuquina-5 y metodos y composiciones que los contienen.
ES2384168T3 (es) * 2002-04-12 2012-07-02 Medarex, Inc. Procedimientos de tratamiento usando anticuerpos CTLA-4
AU2003239356B2 (en) 2002-05-06 2009-06-25 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Identification of novel broadly cross-reactive HIV-1 neutralizing human monoclonal antibodies
AU2003237257A1 (en) 2002-05-24 2003-12-12 Advanced Cell Technology, Inc. A bank of stem cells for transplantation
US20050121254A1 (en) * 2002-05-29 2005-06-09 Marcus Hofmann Device for establishing noise in a motor vehicle
AU2003247135A1 (en) * 2002-07-23 2004-02-09 Nanodiagnostics, Inc. Embryonic stem cell markers and uses thereof
EP2116604A1 (de) 2002-08-05 2009-11-11 University of Rochester Proteinumwandlungsdomäne / Deaminasechimäre Proteine, zugehörige Verbindungen und Verwendungen davon
US20040128703A1 (en) * 2002-09-09 2004-07-01 Hiroaki Shizuya Methods and compositions for the generation of humanized mice
US20080260744A1 (en) 2002-09-09 2008-10-23 Omeros Corporation G protein coupled receptors and uses thereof
US20060134109A1 (en) * 2002-09-09 2006-06-22 Nura Inc. G protein coupled receptors and uses thereof
AU2003282477A1 (en) * 2002-10-07 2004-05-04 Napro Bio Therapeutics, Inc. Methods and compositions for reducing screening in oligonucleotide-directed nucleic acid sequence alteration
US20040077077A1 (en) * 2002-10-18 2004-04-22 Xiangzhong Yang Novel methods for the production of cloned mammals, mammals cloned according to the methods, and methods of use of same
JP2006505291A (ja) * 2002-11-08 2006-02-16 ヘマテック，エルエルシー プリオンタンパク質活性が低減されたトランスジェニック有蹄動物及びその用途
AU2003293015A1 (en) * 2002-11-26 2004-06-18 University Of Utah Research Foundation Microporous materials, methods, and articles for localizing and quantifying analytes
US7597936B2 (en) * 2002-11-26 2009-10-06 University Of Utah Research Foundation Method of producing a pigmented composite microporous material
ES2347239T3 (es) 2002-12-02 2010-10-27 Amgen Fremont Inc. Anticuerpos dirigidos al factor de necrosis tumoral y usos de los mismos.
CA2519528C (en) 2003-03-19 2016-01-26 Abgenix, Inc. Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof
US20050014932A1 (en) 2003-05-15 2005-01-20 Iogenetics, Llc Targeted biocides
US7335496B2 (en) * 2003-06-05 2008-02-26 Ajinomoto Co., Inc. Method for producing target substance
WO2005004794A2 (en) 2003-06-09 2005-01-20 Alnylam Pharmaceuticals Inc. Method of treating neurodegenerative disease
US8790637B2 (en) 2003-06-27 2014-07-29 DePuy Synthes Products, LLC Repair and regeneration of ocular tissue using postpartum-derived cells
US9592258B2 (en) 2003-06-27 2017-03-14 DePuy Synthes Products, Inc. Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
US9572840B2 (en) 2003-06-27 2017-02-21 DePuy Synthes Products, Inc. Regeneration and repair of neural tissue using postpartum-derived cells
KR101581040B1 (ko) 2003-06-27 2015-12-30 암젠 프레몬트 인코포레이티드 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그 용도
US8703121B2 (en) 2003-06-27 2014-04-22 DePuy Synthes Products, LLC Postpartum-derived cells for use in treatment of disease of the heart and circulatory system
US7875272B2 (en) 2003-06-27 2011-01-25 Ethicon, Incorporated Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
CA2535156A1 (en) 2003-08-08 2005-02-24 Abgenix, Inc. Antibodies directed to parathyroid hormone (pth) and uses thereof
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
US7968684B2 (en) * 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
NZ548702A (en) * 2004-01-09 2009-06-26 Pfizer Antibodies to MAdCAM
JP2007518422A (ja) 2004-01-21 2007-07-12 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデーション 変異体ナトリウムチャンネルＮａν１．７およびそれに関連する方法
DE602005026260D1 (de) 2004-03-01 2011-03-24 Immune Disease Inst Inc Natürliche igm-antikörper und inhibitoren davon
AU2005227313A1 (en) 2004-03-19 2005-10-06 Amgen Inc. Reducing the risk of human and anti-human antibodies through V gene manipulation
US7625549B2 (en) * 2004-03-19 2009-12-01 Amgen Fremont Inc. Determining the risk of human anti-human antibodies in transgenic mice
CN101014715A (zh) 2004-04-22 2007-08-08 麒麟麦酒株式会社 转基因动物及其用途
CA2601417C (en) 2004-07-01 2018-10-30 Novo Nordisk A/S Human anti-kir antibodies
JP2008506681A (ja) * 2004-07-16 2008-03-06 ファイザー・プロダクツ・インク 抗ｉｇｆ−１ｒ抗体を用いる非血液性の悪性腫瘍の併用療法
AU2005299413A1 (en) * 2004-10-22 2006-05-04 Revivicor, Inc. Ungulates with genetically modified immune systems
US20080026457A1 (en) * 2004-10-22 2008-01-31 Kevin Wells Ungulates with genetically modified immune systems
JP2008520684A (ja) 2004-11-17 2008-06-19 アブジェニックス・インコーポレーテッド Ｉｌ−１３に対する完全ヒトモノクローナル抗体
ATE476994T1 (de) 2004-11-30 2010-08-15 Curagen Corp Antikörper gegen gpnmb und ihre verwendungen
WO2006068975A2 (en) 2004-12-20 2006-06-29 Abgenix, Inc. Binding proteins specific for human matriptase
WO2006068953A2 (en) 2004-12-21 2006-06-29 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
CA2589063C (en) 2004-12-23 2016-08-09 Ethicon Incorporated Treatment of parkinson's disease and related disorders using postpartum derived cells
EP2361933A3 (de) 2005-01-26 2012-05-02 Amgen Fremont Inc. Antikörper gegen Interleukin-1 Beta
CN101160528A (zh) 2005-02-14 2008-04-09 惠氏公司 Il17-f在诊断和治疗气道炎症中的用途
US20090062190A1 (en) * 2005-02-24 2009-03-05 Salomon Amar Transcriptional Regulation of Cytokines by LITAF and STAT (6)(B)
EP2620450B1 (de) 2005-03-08 2018-11-07 Pfizer Products Inc. Antikörperzusammensetzungen gegen CTLA-4
GT200600148A (es) 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
US7807159B2 (en) * 2005-04-25 2010-10-05 Amgen Fremont Inc. Antibodies to myostatin
UA95775C2 (uk) 2005-04-26 2011-09-12 Пфайзер Инк. Антитіло, яке специфічно зв'язується з р-кадгерином
PL1899364T3 (pl) 2005-05-17 2020-08-24 University Of Connecticut Kompozycje i sposoby immunomodulacji w organizmie
EP1931700B1 (de) 2005-05-19 2013-07-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Funktionelle epitope von streptococcus pneumoniae-psaa-antigen und anwendungen davon
MX2007016032A (es) 2005-06-21 2008-03-10 Xoma Technology Ltd Anticuerpos de enlace a il-1-beta y fragmentos de los mismos.
EP1945257A4 (de) * 2005-08-08 2009-05-06 Onconon Llc Antikörperzusammensetzungen, verfahren zur behandlung von neoplastischer erkrankung und verfahren zur regulierung der fertilität
CN107056943B (zh) * 2005-09-07 2021-06-08 安进弗里蒙特公司 活化素受体样激酶-1的人单克隆抗体
US9388382B2 (en) 2005-10-05 2016-07-12 The Board Of Trustees Of The University Of Illinois Isolation of CD14 negative, CD45 positive and CD117 positive embryonic-like stem cells free of monocytes from human umbilical cord blood mononuclear cells
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
JP2009515897A (ja) 2005-11-10 2009-04-16 キュラジェン コーポレイション Ｔ細胞の免疫グロブリンドメインおよびムチンドメイン１（ｔｉｍ−１）抗原に対する抗体を用いて卵巣癌および腎臓癌を処置する方法
CA2629199C (en) 2005-11-10 2016-08-09 Board Of Supervisors Of Louisiana State University & Agricultural & Mechanical College Compositions and methods for the treatment of addiction and other neuropsychiatry disorders
WO2007067959A2 (en) 2005-12-07 2007-06-14 Medarex, Inc. Ctla-4 antibody dosage escalation regimens
JP5063612B2 (ja) 2005-12-13 2012-10-31 イーライ リリー アンド カンパニー 抗ｉｌ−１７抗体
EP1979001B1 (de) 2005-12-13 2012-04-11 Medimmune Limited Proteine die spezifisch insulin-ähnliche wachstumsfaktoren binden, und deren anwendungen
US10183986B2 (en) 2005-12-15 2019-01-22 Industrial Technology Research Institute Trimeric collagen scaffold antibodies
US20070264687A1 (en) 2005-12-15 2007-11-15 Min-Yuan Chou Recombinant triplex scaffold-based polypeptides
US9175261B2 (en) 2005-12-16 2015-11-03 DePuy Synthes Products, Inc. Human umbilical cord tissue cells for inhibiting adverse immune response in histocompatibility-mismatched transplantation
US9125906B2 (en) 2005-12-28 2015-09-08 DePuy Synthes Products, Inc. Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
NZ599035A (en) 2006-01-12 2013-12-20 Alexion Pharma Inc Antibodies to ox-2/cd200 and uses thereof
CA2644952A1 (en) * 2006-03-01 2007-09-13 The University Of Utah Research Foundation Methods and compositions related to cyclic peptide synthesis
US8470965B2 (en) * 2006-03-01 2013-06-25 University Of Utah Research Foundation Methods and compositions related to cyclic peptide synthesis
CA2638774C (en) * 2006-03-31 2015-11-24 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
AU2007234733A1 (en) * 2006-04-07 2007-10-18 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Antibody compositions and methods for treatment of neoplastic disease
TW200813091A (en) 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
US20100297087A1 (en) * 2006-04-11 2010-11-25 Nanodiagnostics Israel., Ltd Pluripotent stem cells characterized by expression of germline specific genes
CL2007002225A1 (es) 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
JP5362563B2 (ja) * 2006-08-03 2013-12-11 アストラゼネカ・アクチエボラーグ αＶβ６に対する抗体およびその使用
PT2511301T (pt) 2006-08-04 2018-03-08 Medimmune Ltd Anticorpos humanos para erbb2
ES2378407T3 (es) 2006-09-01 2012-04-12 Therapeutic Human Polyclonals, Inc. Aumento de la expresión de inmunoglobulina humana o humanizada en animales transgénicos no humanos
CA2673521C (en) 2006-10-12 2017-01-17 Ethicon, Inc. Kidney-derived cells and methods of use in tissue repair and regeneration
US8835163B2 (en) 2006-10-18 2014-09-16 The Board Of Trustees Of The University Of Illinois Embryonic-like stem cells derived from adult human peripheral blood and methods of use
EP2104516B1 (de) 2006-11-01 2015-01-07 University of Rochester Verfahren und zusammensetzungen in zusammenhang mit der struktur und funktion von apobec3g
US7492312B2 (en) * 2006-11-14 2009-02-17 Fam Adly T Multiplicative mismatched filters for optimum range sidelobe suppression in barker code reception
RU2554747C9 (ru) 2006-12-20 2015-10-20 Ксома (Сша) Ллс Способы лечения il-1бета-зависимых заболеваний
US9101671B2 (en) 2007-01-03 2015-08-11 Sanford-Burnham Medical Research Institute Methods and compositions related to clot binding compounds
CN101679521B (zh) 2007-03-22 2014-03-12 拜奥根Idec马萨诸塞公司 特异性结合cd154的包括抗体、抗体衍生物和抗体片段在内的结合蛋白及其用途
EP2137300B1 (de) 2007-04-26 2011-10-26 Ramot at Tel-Aviv University Ltd. Pluripotente autologe Stammzellen aus der mündlichen oder gastrointestinalen Schleimhaut
CN101688194B (zh) 2007-05-23 2013-09-11 Uab研究基金会 去毒的肺炎球菌神经氨酸酶及其用途
EP2602323B1 (de) 2007-06-01 2018-02-28 Open Monoclonal Technology, Inc. Zusammensetzungen und Verfahren zur Hemmung endogener Immunglobulingene und zur Herstellung transgener menschlicher idiotypischer Antikörper
PT2185719E (pt) 2007-08-02 2014-02-20 Novimmune Sa Anticorpos anti-rantes e processos para a sua utilização
US20100239596A1 (en) * 2007-08-22 2010-09-23 University Of Southern California Grp78 and tumor angiogenesis
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
EP2615113A3 (de) 2007-08-23 2013-11-13 Amgen Inc. Antigenbindende Proteine an Proprotein-Konvertase-Subtilisin/Kexin vom Typ 9 (PCSK9)
WO2009032702A2 (en) 2007-08-28 2009-03-12 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
WO2009032693A2 (en) * 2007-08-28 2009-03-12 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
CN101970485B (zh) * 2007-09-26 2014-05-14 U3制药有限公司 肝素结合表皮生长因子样生长因子抗原结合蛋白
EP2740490A1 (de) 2007-10-03 2014-06-11 Cornell University Behandlung von proliferativen Erkrankungen mit PSMA-Antikörpern
EP2220121B1 (de) 2007-11-12 2015-08-19 U3 Pharma GmbH Axl antikörper
WO2010070380A2 (en) 2007-12-03 2010-06-24 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Of Human Services, National Institutes Of Health Doc1 compositions and methods for treating cancer
KR20100103810A (ko) * 2007-12-10 2010-09-28 알리바 바이오파마수티컬스, 아이엔씨. 동종 재조합에 의한 표적화된 영역의 순차적인 치환 방법
WO2009086003A1 (en) 2007-12-20 2009-07-09 Xoma Technology Ltd. Methods for the treatment of gout
CN102037007A (zh) 2008-01-25 2011-04-27 奥尔胡斯大学 选择性外部位点抑制papp-a对igfbp-4的活性
ES2566750T3 (es) 2008-04-16 2016-04-15 The Johns Hopkins University Método para determinar el riesgo de recidiva de cáncer de próstata
DK2307042T3 (da) 2008-06-25 2014-05-12 Lundbeck & Co As H Modulering af trpv: vps10p-domænereceptorsystem til behandlingen af smerte
JP2011527572A (ja) 2008-07-09 2011-11-04 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｌｉｎｇｏ抗体または断片を含む組成物
AU2008360658B2 (en) 2008-08-15 2015-02-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services S0X9, prostaglandin D2 and retinoic acid for treating pigmentary conditions and melanoma
EP2321351B1 (de) 2008-08-18 2017-11-01 Pfizer Inc. Antikörper gegen ccr2
KR20110057244A (ko) 2008-09-19 2011-05-31 메디뮨 엘엘씨 Ｄｌｌ4에 대한 항체 및 이의 용도
ES2908040T3 (es) * 2008-09-30 2022-04-27 Ablexis Llc Ratones con inserción génica para la producción de anticuerpos quiméricos
EP2348827B1 (de) 2008-10-27 2015-07-01 Revivicor, Inc. Immunsupprimierte huftiere
CA3035432A1 (en) 2008-11-10 2010-05-14 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
EP2370080A1 (de) 2008-12-02 2011-10-05 University of Utah Research Foundation Pde1 als zieltherapeutikum bei herzkrankheiten
CN105641694B (zh) 2008-12-19 2020-08-14 H.隆德贝克有限公司 用于治疗精神和行为障碍的对Vps10p-结构域受体家族的调节
AU2009327384B2 (en) 2008-12-19 2014-07-10 DePuy Synthes Products, LLC Treatment of lung and pulmonary diseases and disorders
US10179900B2 (en) 2008-12-19 2019-01-15 DePuy Synthes Products, Inc. Conditioned media and methods of making a conditioned media
CA2748158A1 (en) 2008-12-23 2010-07-01 Astrazeneca Ab Targeted binding agents directed to .alpha.5.beta.1 and uses thereof
EP2411504B1 (de) 2009-03-26 2017-05-10 DePuy Synthes Products, Inc. Humane nabelschnur gewebezellen in der alzheimer therapie
WO2010112034A2 (en) 2009-04-02 2010-10-07 Aarhus Universitet Compositions and methods for treatment and diagnosis of synucleinopathies
EP3248618A1 (de) 2009-04-22 2017-11-29 Massachusetts Institute Of Technology Angeborene immununterdrückung mit ermöglichung der wiederholten verabreichung von langen rna-molekülen
WO2010128407A2 (en) 2009-05-05 2010-11-11 Novimmune S.A. Anti-il-17f antibodies and methods of use thereof
US8889413B2 (en) 2009-09-30 2014-11-18 DePuy Synthes Products, LLC Mammary artery derived cells and methods of use in tissue repair and regeneration
US8323972B2 (en) 2009-09-30 2012-12-04 Advanced Technologies And Regenerative Medicine, Llc Mammary artery derived cells and methods of use in tissue repair and regeneration
JP2013507365A (ja) 2009-10-07 2013-03-04 サンフォード−バーナム メディカル リサーチ インスティテュート 血餅結合脂質化合物に関する方法および組成物
US20130045192A1 (en) 2009-11-09 2013-02-21 Alexion Pharmaceuticals, Inc. Reagents and methods for detecting pnh type ii white blood cells and their identification as risk factors for thrombotic disorders
CA2780935C (en) 2009-11-13 2022-05-24 U3 Pharma Gmbh Material and methods for treating or preventing her-3 associated diseases
PT2504364T (pt) 2009-11-24 2017-11-14 Medimmune Ltd Agentes de ligação direcionados contra b7-h1
US8912136B2 (en) 2009-12-18 2014-12-16 Sanford-Burnham Medical Research Institute Methods and compositions related to clot-binding compounds
SG182408A1 (en) 2010-01-11 2012-08-30 Alexion Pharma Inc Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
US20110207789A1 (en) 2010-02-19 2011-08-25 Ye Fang Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents
EP2550529B1 (de) 2010-03-23 2021-11-17 Iogenetics, LLC. Bioinformatikverfahren zur bestimmung von peptidbindungen
WO2013040142A2 (en) 2011-09-16 2013-03-21 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
DK2553100T3 (en) 2010-03-31 2017-10-23 Ablexis Llc REPLACING NON-HUMAN ANIMALS TO CREATE CHIMERARY ANTIBODIES
MX340696B (es) 2010-04-30 2016-07-21 Alexion Pharma Inc Anticuerpos anti-c5a y metodos para usar los anticuerpos.
EP2569335B1 (de) 2010-05-14 2018-08-22 Orega Biotech Verfahren zur behandlung und/oder prävention von zellproliferationsstörungen mit il-17-antagonisten
EP2392208B1 (de) * 2010-06-07 2016-05-04 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Fusionsproteine, die eine DNA-Bindungsdomäne eines TAL-Effektorproteins und eine unspezifische Spaltungsdomäne einer Restriktionsnuklease umfassen, und deren Verwendung
JP2013533243A (ja) 2010-06-22 2013-08-22 ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレート 補体成分３のＣ３ｄ断片に対する抗体
GB201012420D0 (en) 2010-07-23 2010-09-08 Univ Erasmus Medical Ct Foetal heamoglobin inhibitor
GB201012410D0 (en) 2010-07-23 2010-09-08 Medical Res Council Intracellular immunity
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
DK2597945T3 (da) 2010-07-26 2020-09-21 Trianni Inc Transgene dyr og fremgangsmåder til anvendelse deraf
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
CA2815154A1 (en) 2010-08-06 2012-02-09 U3 Pharma Gmbh Use of her3 binding agents in prostate treatment
EP2603526A1 (de) 2010-08-13 2013-06-19 Medimmune Limited Monomere polypeptide mit abweichenden fc-regionen und verwendungsverfahren
WO2012022734A2 (en) 2010-08-16 2012-02-23 Medimmune Limited Anti-icam-1 antibodies and methods of use
SG192047A1 (en) 2011-01-24 2013-08-30 Univ Singapore Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
AR085141A1 (es) 2011-02-03 2013-09-11 Alexion Pharma Inc Un metodo para prolongar la supervivencia de un aloinjerto renal, uso de un anticuerpo anti-cd200 para prolongar la supervivencia de aloinjertos
US9051619B2 (en) 2011-03-25 2015-06-09 Florida Agricultural and Mechanical University (FAMU) Methods and compositions for prostate cancer metastasis
CA2831247C (en) 2011-03-31 2020-07-21 Oriental Yeast Co., Ltd. Cancer immunopotentiating agent containing rankl antagonist
WO2012138997A1 (en) 2011-04-07 2012-10-11 Amgen Inc. Novel egfr binding proteins
WO2012142164A1 (en) 2011-04-12 2012-10-18 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
JP6400470B2 (ja) 2011-05-16 2018-10-03 ジェネロン（シャンハイ）コーポレイション リミテッド 多重特異性Ｆａｂ融合タンパク質および使用法
CN105601748B (zh) 2011-07-01 2021-08-27 恩格姆生物制药公司 用于代谢病症和疾病治疗的组合物、应用和方法
WO2013012855A1 (en) 2011-07-18 2013-01-24 Amgen Inc. Apelin antigen-binding proteins and uses thereof
EP2773667A1 (de) 2011-11-01 2014-09-10 Bionomics, Inc. Anti-gpr49-antikörper
CN104053671A (zh) 2011-11-01 2014-09-17 生态学有限公司 治疗癌症的抗体和方法
AU2012332590B2 (en) 2011-11-01 2016-10-20 Bionomics, Inc. Anti-GPR49 antibodies
US10598653B2 (en) 2011-11-01 2020-03-24 Bionomics Inc. Methods of blocking cancer stem cell growth
US20140286959A1 (en) 2011-11-08 2014-09-25 Pfizer Inc. Methods of Treating Inflammatory Disorders Using Anti-M-CSF Antibodies
EA201490974A1 (ru) 2011-11-16 2014-09-30 Эмджен Инк. СПОСОБЫ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С ДЕЛЕЦИОННЫМ МУТАНТОМ vIII ЭПИДЕРМАЛЬНОГО ФАКТОРА РОСТА
EP3050900A1 (de) 2011-12-19 2016-08-03 Xoma (Us) Llc Verfahren zur behandlung von akne
US9611513B2 (en) 2011-12-23 2017-04-04 DePuy Synthes Products, Inc. Detection of human umbilical cord tissue derived cells
EP3578569A1 (de) 2012-02-06 2019-12-11 Inhibrx, Inc. Cd47-antikörper und verfahren zur verwendung davon
GB201202268D0 (en) 2012-02-09 2012-03-28 Medical Res Council Intracellular immunity
WO2013155447A1 (en) 2012-04-13 2013-10-17 Children's Medical Center Corporation Tiki inhibitors
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
JP2015518829A (ja) 2012-05-14 2015-07-06 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 運動ニューロンに関する状態の処置のためのｌｉｎｇｏ−２アンタゴニスト
JP2015525230A (ja) 2012-06-11 2015-09-03 アムジエン・インコーポレーテツド デュアル受容体アンタゴニスト性抗原結合タンパク質およびその使用
EP2863948B1 (de) 2012-06-22 2018-10-24 Cytomx Therapeutics Inc. Anti-jagged-1/jagged-2-kreuzreaktive antikörper, aktivierbare anti-jagged-antikörper und anwendungsverfahren dafür
US9457071B2 (en) 2012-06-28 2016-10-04 Hiroshima University Histamine releaser contained in human sweat
JP6385005B2 (ja) 2012-08-17 2018-09-05 国立大学法人広島大学 汗アレルギー抗原蛋白質に結合するモノクローナルＩｇＥ抗体
WO2014034700A1 (ja) 2012-08-30 2014-03-06 国立大学法人広島大学 BBF2H7(BBF2 human homologue on chromosome7)部分アミノ酸配列を有するペプチドまたはそれに結合する抗体を含む細胞増殖調節用組成物
CA2887682A1 (en) 2012-10-09 2014-04-17 Biogen Idec Ma Inc. Combination therapies and uses for treatment of demyelinating disorders
EP2925775B1 (de) 2012-11-28 2020-09-16 NGM Biopharmaceuticals, Inc. Zusammensetzungen und verfahren zur behandlung von stoffwechselerkrankungen und -leiden
AU2013370404B2 (en) 2012-12-27 2017-11-02 Ngm Biopharmaceuticals, Inc. Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US9920121B2 (en) 2013-01-25 2018-03-20 Amgen Inc. Antibodies targeting CDH19 for melanoma
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
SG11201506132PA (en) 2013-02-06 2015-09-29 Inhibrx Llc Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
RU2015137617A (ru) 2013-03-14 2017-04-18 Юниверсити Оф Мэриленд, Балтимор Офис Оф Текнолоджи Трансфер Агенты, подавляющие андрогенные рецепторы, и их применение
WO2014140368A1 (en) 2013-03-15 2014-09-18 Amgen Research (Munich) Gmbh Antibody constructs for influenza m2 and cd3
EP3653642A1 (de) 2013-03-15 2020-05-20 Amgen Research (Munich) GmbH Einbettige bindemoleküle mit n-terminalen ab
EP3013422A1 (de) 2013-06-28 2016-05-04 Amgen Inc. Verfahren zur behandlung von homozygoter familiärer hypercholesterolämie
CA2920317A1 (en) 2013-08-12 2015-02-19 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
US10077304B2 (en) 2013-08-14 2018-09-18 The Governing Council Of The University Of Toronto Antibodies against frizzled receptor
WO2015050959A1 (en) 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
NL2011912C2 (en) * 2013-12-06 2015-06-09 Univ Delft Tech Novel genome alteration system for microorganisms.
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
AU2015217572B2 (en) 2014-02-11 2020-10-15 Visterra, Inc. Antibody moleules to dengue virus and uses thereof
BR112016018408A2 (pt) 2014-03-14 2017-12-26 Immutep Sas moléculas de anticorpo à lag-3 e usos das mesmas
MX2016012873A (es) 2014-04-04 2017-03-07 Bionomics Inc Anticuerpos humanizados que se unen al receptor 5 acoplado a proteina g que contiene repeticion rica en leucina (lgr5).
EP3888690A3 (de) 2014-05-16 2021-10-20 MedImmune, LLC Moleküle mit veränderter neonater fc-rezeptorbindung mit verbesserten therapeutischen und diagnostischen eigenschaften
WO2015179404A1 (en) 2014-05-19 2015-11-26 The Johns Hopkins University Methods for identifying androgen receptor splice variants in subjects having castration resistant prostate cancer
PL3152312T3 (pl) 2014-06-06 2020-08-10 Regeneron Pharmaceuticals, Inc. Sposoby i kompozycje do modyfikowania docelowego locus
TWI695011B (zh) 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 抗ｈｅｒ２表位之單株抗體及其使用之方法
US11661462B2 (en) 2014-07-31 2023-05-30 Amgen Research (Munich) Gmbh Optimized cross-species specific bispecific single chain antibody contructs
AR101400A1 (es) 2014-07-31 2016-12-14 Amgen Res (Munich) Gmbh Constructo de anticuerpo de cadena individual biespecífico con distribución mejorada de tejido
MX2017001432A (es) 2014-07-31 2017-05-09 Uab Res Found Peptidos mimeticos de la apoe y mayor potencia para depurar el colesterol en plasma.
UY36245A (es) 2014-07-31 2016-01-29 Amgen Res Munich Gmbh Constructos de anticuerpos para cdh19 y cd3
JP6860476B2 (ja) 2014-08-25 2021-04-14 ザ ジョンズ ホプキンズ ユニヴァーシティー 前立腺がん治療に関する方法及び組成物
US9993551B2 (en) 2014-09-13 2018-06-12 Novartis Ag Combination therapies of EGFR inhibitors
US20170209574A1 (en) 2014-10-03 2017-07-27 Novartis Ag Combination therapies
UY36351A (es) 2014-10-14 2016-06-01 Novartis Ag Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
SG11201702757YA (en) 2014-10-23 2017-05-30 Ngm Biopharmaceuticals Inc Pharmaceutical compositions comprising peptide variants and methods of use thereof
EP3020273B1 (de) * 2014-11-17 2018-07-04 Competence Centre on Health Technologies Verfahren zur herstellung biotechnologischer arzneimittel unter verwendung transgener rinder
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
SG11201704646YA (en) * 2014-12-19 2017-07-28 Regeneron Pharma Methods and compositions for targeted genetic modification through single-step multiple targeting
WO2016112270A1 (en) 2015-01-08 2016-07-14 Biogen Ma Inc. Lingo-1 antagonists and uses for treatment of demyelinating disorders
KR20180023892A (ko) 2015-04-17 2018-03-07 암젠 리서치 (뮌헨) 게엠베하 Cdh3 및 cd3에 대한 이중 특이성 항체 작제물
CN107921188A (zh) 2015-05-18 2018-04-17 小利兰·斯坦福大学托管委员会 用于治疗衰老相关的损伤的方法和组合物
JP2018080114A (ja) 2015-05-29 2018-05-24 株式会社アールテック・ウエノ 抗ヒトｖａｐ−１モノクローナル抗体
WO2017019894A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to lag-3
EP3316902A1 (de) 2015-07-29 2018-05-09 Novartis AG Kombinationstherapien mit antikörpermolekülen gegen tim-3
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TW202346349A (zh) 2015-07-31 2023-12-01 德商安美基研究（慕尼黑）公司 Dll3及cd3抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
WO2017035241A1 (en) 2015-08-24 2017-03-02 Trianni, Inc. Enhanced production of immunoglobulins
JP6728352B2 (ja) 2015-11-09 2020-07-22 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 胆汁酸に関係した障害の治療方法
JP7041628B2 (ja) 2015-11-10 2022-03-24 ビステラ， インコーポレイテッド リポ多糖に特異的に結合する抗体分子－薬物コンジュゲートおよびその使用
PL3380522T3 (pl) 2015-11-25 2024-03-25 Visterra, Inc. Cząsteczki przeciwciał wobec april i ich zastosowania
EP3384030A4 (de) 2015-12-03 2019-07-03 Trianni, Inc. Verbesserte immunglobulindiversität
MX2018007423A (es) 2015-12-17 2018-11-09 Novartis Ag Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas.
CN108601819B (zh) 2015-12-17 2022-03-15 约翰霍普金斯大学 用死亡受体激动剂改善系统性硬化症
CN108697794A (zh) 2015-12-17 2018-10-23 诺华股份有限公司 C-met抑制剂和抗pd-1抗体分子的组合及其用途
EA039859B1 (ru) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
IL260920B (en) 2016-02-03 2022-09-01 Amgen Res Munich Gmbh Constructs of psma and cd3 bispecific antigens that bind to t-cells, preparations containing them and uses thereof
EP4039709A1 (de) 2016-02-03 2022-08-10 Amgen Research (Munich) GmbH Bcma- und cd3-bispezifische t-zell-aktivierende antikörperkonstrukte
JP6929877B2 (ja) 2016-02-04 2021-09-01 トリアニ・インコーポレイテッドＴｒｉａｎｎｉ， Ｉｎｃ． 免疫グロブリン産生の増強
WO2017151517A1 (en) 2016-02-29 2017-09-08 Foundation Medicine, Inc. Methods of treating cancer
WO2017158421A1 (en) 2016-03-14 2017-09-21 University Of Oslo Anti-viral engineered immunoglobulins
GEP20217232B (en) 2016-03-14 2021-03-25 I Oslo Universitetet Engineered immunoglobulins with altered fcrn binding
CN109476756B (zh) 2016-03-15 2022-05-31 埃泰美德(香港)有限公司 一种多特异性Fab融合蛋白及其用途
JP7137474B2 (ja) 2016-03-15 2022-09-14 メルサナ セラピューティクス，インコーポレイティド ＮａＰｉ２ｂ標的化抗体－薬物コンジュゲート及びその使用方法
WO2017158436A1 (en) 2016-03-17 2017-09-21 Oslo Universitetssykehus Hf Fusion proteins targeting tumour associated macrophages for treating cancer
JP7082604B2 (ja) 2016-03-21 2022-06-08 マレンゴ・セラピューティクス，インコーポレーテッド 多重特異性および多機能性分子ならびにその使用
KR20180138205A (ko) 2016-03-22 2018-12-28 바이오노믹스 리미티드 항-lgr5 단클론성 항체의 투여
TW202302144A (zh) 2016-03-25 2023-01-16 美商威特拉公司 登革病毒的抗體分子之配方設計
JP7281795B2 (ja) 2016-04-07 2023-05-26 ザ・ジョンズ・ホプキンス・ユニバーシティー 膵炎および疼痛をデス受容体アゴニストで処置するための組成物および方法
US20170298119A1 (en) 2016-04-15 2017-10-19 Visterra, Inc. Antibody molecules to zika virus and uses thereof
JOP20170091B1 (ar) 2016-04-19 2021-08-17 Amgen Res Munich Gmbh إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
US11780924B2 (en) 2016-06-21 2023-10-10 University Of Oslo HLA binding vaccine moieties and uses thereof
EP3484512A1 (de) 2016-07-13 2019-05-22 Biogen MA Inc. Dosierungspläne von lingo-1-antagonisten und verwendung zur behandlung von demyelinisierungserkrankungen
US11858980B2 (en) 2016-08-02 2024-01-02 Visterra, Inc. Engineered polypeptides and uses thereof
TW201825511A (zh) 2016-09-09 2018-07-16 美商艾斯合顧問有限公司 表現免疫檢查點調節子的溶瘤病毒
EP3515936A1 (de) 2016-09-23 2019-07-31 Elstar Therapeutics, Inc. Multispezifische antikörpermoleküle mit lambda- und kappa- leichtketten
JP7239179B2 (ja) 2016-10-05 2023-03-14 ユニバーシティ オブ セントラル フロリダ リサーチ ファウンデーション，インコーポレイテッド Ｎｋ細胞および抗ｐｄｌ１による癌治療法に関連する方法および組成物
JP7360324B2 (ja) 2016-12-23 2023-10-12 ビステラ， インコーポレイテッド 結合ポリペプチドおよびそれを作製する方法
US11890319B2 (en) 2017-01-18 2024-02-06 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
JOP20190189A1 (ar) 2017-02-02 2019-08-01 Amgen Res Munich Gmbh تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
WO2018151820A1 (en) 2017-02-16 2018-08-23 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
WO2018158719A1 (en) 2017-03-02 2018-09-07 Novartis Ag Engineered heterodimeric proteins
JP7048629B2 (ja) 2017-03-10 2022-04-05 エンベラ ニューロセラピューティクス，インコーポレイティド 医薬組成物およびその使用
AU2018249493A1 (en) 2017-04-03 2019-09-19 Oncxerna Therapeutics, Inc. Methods for treating cancer using PS-targeting antibodies with immuno-oncology agents
CN110709422B (zh) 2017-04-19 2023-12-26 马伦戈治疗公司 多特异性分子及其用途
EP3615052B1 (de) 2017-04-27 2023-01-25 The University of Hong Kong Verwendung von hcn-inhibitoren zur behandlung von krebs
EP3615068A1 (de) 2017-04-28 2020-03-04 Novartis AG Auf bcma abzielender wirkstoff und kombinationstherapie mit einem gamma-sekretase-inhibitor
WO2018201047A1 (en) 2017-04-28 2018-11-01 Elstar Therapeutics, Inc. Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
KR20190141243A (ko) 2017-05-05 2019-12-23 암젠 인크 개선된 저장 및 투여를 위한 이중특이적 항체 구축물을 포함하는 약제학적 조성물
WO2018222901A1 (en) 2017-05-31 2018-12-06 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
CA3066774A1 (en) 2017-06-22 2018-12-27 Novartis Ag Antibody molecules to cd73 and uses thereof
US20200172628A1 (en) 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
CN111050791A (zh) 2017-06-27 2020-04-21 诺华股份有限公司 用于抗tim-3抗体的给药方案及其用途
CN111032694B (zh) 2017-07-14 2024-03-08 辉瑞大药厂 针对madcam的抗体
EP3431496A1 (de) 2017-07-19 2019-01-23 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anti-isoasp7-amyloid-beta-antikörper und verwendungen davon
WO2019018730A1 (en) 2017-07-20 2019-01-24 Novartis Ag DOSAGE REGIMES FOR ANTI-LAG3 ANTIBODIES AND USES THEREOF
CA3066793C (en) 2017-07-21 2023-06-20 Werner Mueller Single chain vh and heavy chain antibodies
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
EP3461841B1 (de) 2017-10-02 2019-09-11 Certest Biotec, S.L. Antikörper gegen dps und testvorrichtungen zum nachweis von bakterien der gattung campylobacter
AU2018345637A1 (en) 2017-10-02 2020-03-05 Visterra, Inc. Antibody molecules to CD138 and uses thereof
CA3078155A1 (en) 2017-10-19 2019-04-25 Debiopharm International S.A. Combination product for the treatment of cancer
DK3476942T3 (da) 2017-10-27 2022-04-19 Trianni Inc Lange kimlinje-dh-gener og antistoffer med lang hcdr3
JP2021503478A (ja) 2017-11-16 2021-02-12 ノバルティス アーゲー 組み合わせ治療
WO2019113464A1 (en) 2017-12-08 2019-06-13 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
US20210163592A1 (en) 2017-12-11 2021-06-03 Amgen Inc Continuous manufacturing process for bispecific antibody products
WO2019129137A1 (zh) 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 抗lag-3抗体及其用途
WO2019129136A1 (zh) 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 抗pd-l1抗体及其用途
CN115925943A (zh) 2017-12-27 2023-04-07 信达生物制药(苏州)有限公司 抗pd-l1抗体及其用途
TW201940518A (zh) 2017-12-29 2019-10-16 美商安進公司 針對ｍｕｃ１７和ｃｄ３之雙特異性抗體構建體
WO2019178364A2 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
US20210238280A1 (en) 2018-03-14 2021-08-05 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
BR112020026033A2 (pt) 2018-06-19 2021-03-23 Atarga, Llc moléculas de anticorpo para complementar o componente 5 e usos das mesmas
CN112638427A (zh) 2018-06-29 2021-04-09 北卡罗莱纳州立大学 用于术后治疗的原位喷雾生物响应性免疫治疗凝胶
EP3818083A2 (de) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr-antikörpermoleküle und ihre verwendungen
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
MA53325A (fr) 2018-07-30 2021-06-09 Amgen Inc Administration prolongée d'une construction d'anticorps bispécifique se liant à cd33 et cd3
CN112512581A (zh) 2018-08-03 2021-03-16 安进研发（慕尼黑）股份有限公司 针对cldn18.2和cd3的抗体构建体
BR112021003436A2 (pt) 2018-08-27 2021-05-18 Affimed Gmbh células nk criopreservadas pré-carregadas com uma construção de anticorpo
WO2020069372A1 (en) 2018-09-27 2020-04-02 Elstar Therapeutics, Inc. Csf1r/ccr2 multispecific antibodies
WO2020077212A1 (en) 2018-10-11 2020-04-16 Amgen Inc. Downstream processing of bispecific antibody constructs
JP2022514017A (ja) 2018-12-20 2022-02-09 ノバルティス アーゲー 医薬の組み合わせ
US10871640B2 (en) 2019-02-15 2020-12-22 Perkinelmer Cellular Technologies Germany Gmbh Methods and systems for automated imaging of three-dimensional objects
GB2597851A (en) 2019-02-21 2022-02-09 Marengo Therapeutics Inc Antibody molecules that bind to NKP30 and uses thereof
EP3927744A1 (de) 2019-02-21 2021-12-29 Marengo Therapeutics, Inc. Multifunktionelle moleküle, die an t-zell-verwandte krebszellen binden, und verwendungen davon
GB2599227A (en) 2019-02-21 2022-03-30 Marengo Therapeutics Inc Multifunctional molecules that bind to T cells and uses thereof to treat autoimmune disorders
SG11202109056TA (en) 2019-02-21 2021-09-29 Marengo Therapeutics Inc Multifunctional molecules that bind to calreticulin and uses thereof
CA3131014A1 (en) 2019-02-21 2020-08-27 Andreas Loew Anti-tcr antibody molecules and uses thereof
SG11202110732XA (en) 2019-03-29 2021-10-28 Atarga Llc Anti fgf23 antibody
MX2021014644A (es) 2019-06-13 2022-04-06 Amgen Inc Control de perfusion basado en biomasa automatizado en la fabricacion de productos biologicos.
BR112021025421A2 (pt) 2019-06-17 2022-02-01 Visterra Inc Moléculas de anticorpo humanizado para cd138 e os usos dos mesmos
US11660330B2 (en) 2019-06-21 2023-05-30 H. Lee Moffitt Cancer Center And Research Institute, Inc. Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapy
AU2020299569A1 (en) 2019-07-01 2022-01-20 Trianni, Inc. Transgenic mammals and methods of use
CA3144958A1 (en) 2019-07-01 2021-01-07 Trianni, Inc. Transgenic mammals and methods of use thereof
MX2022000988A (es) 2019-07-26 2022-05-03 Amgen Inc Proteinas de union a antigeno anti-il13.
TW202118774A (zh) 2019-07-26 2021-05-16 美商威特拉公司 介白素-2藥劑及其用途
EP3785536B1 (de) 2019-08-28 2022-01-26 Trianni, Inc. Adam6-knockin-mäuse
CA3152946A1 (en) 2019-09-10 2021-03-18 Amgen Inc. Purification method for bispecific antigen-binding polypeptides with enhanced protein l capture dynamic binding capacity
TW202128166A (zh) 2019-10-21 2021-08-01 瑞士商諾華公司 組合療法
KR20220087498A (ko) 2019-10-21 2022-06-24 노파르티스 아게 Tim-3 억제제 및 그의 용도
WO2021097344A1 (en) 2019-11-13 2021-05-20 Amgen Inc. Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
CN115175936A (zh) 2019-12-20 2022-10-11 安进公司 用于治疗实体瘤的靶向间皮素的cd40激动性多特异性抗体构建体
CN115175937A (zh) 2019-12-20 2022-10-11 诺华股份有限公司 用于治疗骨髓纤维化和骨髓增生异常综合征的抗TIM-3抗体MBG453和抗TGF-β抗体NIS793与或不与地西他滨或抗PD-1抗体斯巴达珠单抗的组合
KR20220119467A (ko) 2019-12-27 2022-08-29 아피메트 게엠베하 이중특이적 fcyriii x cd30 항체 작제물의 제조 방법
EP4084821A2 (de) 2020-01-03 2022-11-09 Marengo Therapeutics, Inc. An cd33 bindende multifunktionsmoleküle und ihre verwendungen
TW202140553A (zh) 2020-01-13 2021-11-01 美商威特拉公司 C5ar1抗體分子及其用途
WO2021144657A1 (en) 2020-01-17 2021-07-22 Novartis Ag Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
WO2021150824A1 (en) 2020-01-22 2021-07-29 Amgen Research (Munich) Gmbh Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
WO2021183861A1 (en) 2020-03-12 2021-09-16 Amgen Inc. Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor
WO2021188851A1 (en) 2020-03-19 2021-09-23 Amgen Inc. Antibodies against mucin 17 and uses thereof
AU2021248643A1 (en) 2020-04-03 2022-10-27 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
EP4143224A1 (de) 2020-05-01 2023-03-08 Novartis AG Immunglobulinvarianten
EP4143236A1 (de) 2020-05-01 2023-03-08 Novartis AG Manipulierte immunglobuline
US11850421B2 (en) 2020-05-08 2023-12-26 Novocure Gmbh Compositions and methods of applying alternating electric fields to pluripotent stem cells
JP2023527293A (ja) 2020-05-19 2023-06-28 アムジエン・インコーポレーテツド Ｍａｇｅｂ２結合構築物
JP2023527972A (ja) 2020-05-29 2023-07-03 アムジエン・インコーポレーテツド Ｃｄ３３及びｃｄ３に結合する二重特異性コンストラクトの有害作用軽減投与
JP2023531722A (ja) 2020-06-24 2023-07-25 ビステラ， インコーポレイテッド Ａｐｒｉｌに対する抗体分子およびその使用
WO2022026592A2 (en) 2020-07-28 2022-02-03 Celltas Bio, Inc. Antibody molecules to coronavirus and uses thereof
AU2021331076A1 (en) 2020-08-26 2023-04-06 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
GB2616354A (en) 2020-08-26 2023-09-06 Marengo Therapeutics Inc Methods of detecting TRBC1 or TRBC2
EP4204450A2 (de) 2020-08-26 2023-07-05 Marengo Therapeutics, Inc. An calreticulin bindende multifunktionelle moleküle und verwendungen davon
EP4204020A1 (de) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Verfahren zur behandlung von psma-exprimierenden krebsarten
EP4204021A1 (de) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Verfahren zur behandlung von psma-exprimierenden krebsarten
CN116368154A (zh) 2020-10-08 2023-06-30 阿菲姆德股份有限公司 三特异性结合剂
US20230406887A1 (en) 2020-11-06 2023-12-21 Amegen Inc. Antigen binding domain with reduced clipping rate
MX2023005323A (es) 2020-11-06 2023-05-19 Amgen Inc Construcciones polipeptidicas que se unen a cd3.
TW202233679A (zh) 2020-11-06 2022-09-01 德商安美基研究（慕尼黑）公司 選擇性地與cldn6和cd3結合的多肽構建體
CA3200317A1 (en) 2020-11-06 2022-05-12 Amgen Inc. Multitargeting bispecific antigen-binding molecules of increased selectivity
WO2022120224A1 (en) 2020-12-04 2022-06-09 Visterra, Inc. Methods of using interleukin-2 agents
KR20230150779A (ko) 2020-12-09 2023-10-31 트리아니, 인코포레이티드 중쇄-단독 항체
JP2024503506A (ja) 2021-01-20 2024-01-25 ビステラ， インコーポレイテッド インターロイキン－２変異体およびその使用
EP4284510A1 (de) 2021-01-29 2023-12-06 Novartis AG Dosierungsschemata für anti-cd73- und anti-enpd2-antikörper und verwendungen davon
WO2022182872A2 (en) 2021-02-24 2022-09-01 Alladapt Immunotherapeutics, Inc. Compositions and methods for identification of cross-reactive allergenic proteins and treatment of allergies
WO2022195551A1 (en) 2021-03-18 2022-09-22 Novartis Ag Biomarkers for cancer and methods of use thereof
TW202313681A (zh) 2021-04-02 2023-04-01 美商安進公司 Ｍａｇｅｂ２結合構建體
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
BR112023020832A2 (pt) 2021-04-08 2023-12-19 Marengo Therapeutics Inc Moléculas multifuncionais ligadas a tcr e seus usos
KR20240004503A (ko) 2021-05-05 2024-01-11 트리아니, 인코포레이티드 키메라 말-설치류 항체를 발현하는 유전자이식 설치류 및 이의 사용 방법
WO2022235929A1 (en) 2021-05-05 2022-11-10 Radius Pharmaceuticals, Inc. Animal model having homologous recombination of mouse pth1 receptor
CN117279947A (zh) 2021-05-06 2023-12-22 安进研发（慕尼黑）股份有限公司 用于在增殖性疾病中使用的靶向cd20和cd22的抗原结合分子
WO2023007023A1 (en) 2021-07-30 2023-02-02 Affimed Gmbh Duplexbodies
WO2023044483A2 (en) 2021-09-20 2023-03-23 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
WO2023056430A1 (en) 2021-10-01 2023-04-06 Abcellera Biologics Inc. Transgenic rodents for cell line identification and enrichment
WO2023079493A1 (en) 2021-11-03 2023-05-11 Affimed Gmbh Bispecific cd16a binders
AR127568A1 (es) 2021-11-03 2024-02-07 Affimed Gmbh Ligandos biespecíficos de cd16a
WO2023086815A1 (en) 2021-11-10 2023-05-19 Trianni, Inc. Transgenic mammals and methods of use thereof
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2023097254A1 (en) 2021-11-24 2023-06-01 Visterra, Inc. Engineered antibody molecules to cd138 and uses thereof
TW202333772A (zh) 2021-12-01 2023-09-01 美商威特拉公司 使用介白素-2藥劑之方法
WO2023139292A1 (en) 2022-01-24 2023-07-27 Cambridge Enterprise Limited Tau therapy
WO2023150778A1 (en) 2022-02-07 2023-08-10 Visterra, Inc. Anti-idiotype antibody molecules and uses thereof
US20240092921A1 (en) 2022-04-25 2024-03-21 Visterra, Inc. Antibody molecules to april and uses thereof
TW202346368A (zh) 2022-05-12 2023-12-01 德商安美基研究（慕尼黑）公司 具有增加的選擇性的多鏈多靶向性雙特異性抗原結合分子
WO2023220695A2 (en) 2022-05-13 2023-11-16 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
EP4296279A1 (de) 2022-06-23 2023-12-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anti-transthyretin(ttr)-bindende proteine und ihre verwendungen
WO2024030976A2 (en) 2022-08-03 2024-02-08 Voyager Therapeutics, Inc. Compositions and methods for crossing the blood brain barrier
WO2024059675A2 (en) 2022-09-14 2024-03-21 Amgen Inc. Bispecific molecule stabilizing composition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3806617A1 (de) * 1988-03-02 1989-09-14 Behringwerke Ag Erzeugung hochexprimierender, rekombinanter, eukaryotischer zellen
JPH04500909A (ja) * 1988-09-21 1992-02-20 アニマル　バイオテクノロジー　ケンブリッジ　リミティド 家畜からの多能性胚細胞系の誘導
GB8826446D0 (en) * 1988-11-11 1988-12-14 Agricultural & Food Res Peptide production
CA2006011A1 (en) * 1988-12-21 1990-06-21 Cecilia Lo Transgenic organisms and cells and methods of producing transgenic organisms and cells
EP0535144A4 (en) * 1990-06-12 1993-08-11 Baylor College Of Medicine Method for homologous recombination in animal and plant cells

Also Published As

Publication number Publication date
EP0546091A1 (de) 1993-06-16
ATE352612T1 (de) 2007-02-15
AU664976B2 (en) 1995-12-14
EP0546091B1 (de) 2007-01-24
EP0546091A4 (en) 1993-12-29
WO1992003917A1 (en) 1992-03-19
US5721367A (en) 1998-02-24
US5612205A (en) 1997-03-18
JPH06506105A (ja) 1994-07-14
CA2090473A1 (en) 1992-03-01
AU8649791A (en) 1992-03-30

Similar Documents

Publication Publication Date Title
DE69133557D1 (de) Homologe rekombination in säugetier-zellen
ATE198621T1 (de) Herstellung und verwendung von transgenen mäusen mit fehlender expression von cd28
DK0463151T3 (da) Frembringelse af xenogene antistoffer
NO812896L (no) Brenselcellegenerator
DE3887085T2 (de) Herstellung von schimären Antikörpern durch homologe Rekombination.
ATE253112T1 (de) Menschliche hematopoietische stammzellen
DK16984D0 (da) Braendselscelle
NO975674D0 (no) Fremgangsmåte for å regulere sialyleringen av proteiner fremstilt av pattedyrceller i kultur
BR8102276A (pt) Celula de combustivel
NZ210106A (en) Immunological compositions containing anti-idiotype antibodies
IT7948574A0 (it) Composizioni in due parti per la riparazione di rivestimenti di cavi
ES507008A0 (es) Perfeccionamientos en los sistemas electricos de produccion y-o almacenaje de energia.
AU520928B2 (en) Compensating the magnetic field induced by the adjacent line in series of high intensity electrolysis cells
GB2099450B (en) High density fuel compositions
ES506664A0 (es) Perfeccionamientos en los sistemas electricos de produccion y-o almacenaje de energia
DK323088A (da) Koeleanlaeg til braendeselsceller
PT765398E (pt) Populacao de celulas enriquecedoras em progenitores mieloides e linfoides e metodos de as fazer e utilizar
IT1137021B (it) Stadio di uscita in controfase
ES2047946T3 (es) Metodos de cultivos celulares para producir proteina c activada.
DK0427869T3 (da) Energiproducerende brændselscellesystem
ES457653A1 (es) Un procedimiento para la preparacion de nuevas trans-octahi-dropirido-pirrolo-benzazepinas 3-sustituidas.
NO791279L (no) Boelgekraftverk med kunstig regulerbar bunn
IT8016507A0 (it) Metodo e impianto per produrre energia elettrica con l'energia di marea
JPS56133586A (en) Method of crushing laminated scale in furnace beam
BR6400753U (pt) Aperfeicoamento em velas combustiveis

Legal Events

Date Code Title Description
8332 No legal effect for de